Completed PHASE3 INTERVENTIONAL 2-arm NCT00974974

A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).

A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease

Sponsor: Impax Laboratories, LLC

Updated 10 times since 2017 Last updated: Aug 7, 2020 Started: Sep 30, 2009 Primary completion: Jan 31, 2011 Completion: Mar 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Parkinson's Disease, this trial is completed. The trial is conducted by Impax Laboratories, LLC and has accumulated 10 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Sep 2020 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 5 earlier versions

Dec 2019 — Sep 2020 [monthly]

Completed PHASE3
Jul 2019 — Dec 2019 [monthly]

Completed PHASE3
Jun 2018 — Jul 2019 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Impax Laboratories, LLC

Data source: Impax Laboratories, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Augusta, United States , Aurora, United States , Barcelona, Spain , Berlin, Germany , Bingham Farms, United States , Birmingham, United States , Boise, United States , Bradenton, United States , Brasov, Romania and 53 more locations